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In this edition, the “Down-staging following neoadjuvant chemo-radiotherapy (NACTRT) for locally
advanced rectal cancer — does the timing of surgery really matter?” aims to look at a topical issue. A
retrospective analysis was undertaken of 110 patients. The authors reported a wide variation in the timing of
surgery following completion of NACTRT, 4-474 days (median: 64.5). Patients were divided into those
having surgery within 60 days (n = 42) or thereafter (n = 68). The authors demonstrated no difference in
pathological variables (pathological complete response, tumor regression grade, circumferential resection
margin status, lymph nodes or lymphovascular invasion) between the two groups. They also concluded that
there was no significant difference in sphincter-saving surgery (62% vs. 53%) or early recurrence rates
(median follow-up 13 months (range: 4-27).
A study such as this, with a small sample size, lack of power and retrospective analysis limit the conclusions
but raise some interesting issues. To understand whether or not the timing of surgery after radiotherapy alters
practice-there needs to be a comparison between the pretreatment tumor (T) and nodal (N) stage with the
pathological specimen, or posttreatment imaging — hence, we are not really sure where and how “down-
staging” occurs. Crucially, if no restaging after chemo/radiotherapy takes place then it is highly unlikely that
the surgical treatment plan will be altered. Thus, it is not possible to infer what effects may, or may not have
on sphincter saving surgery or early local recurrence. However, the observation of an extremely wide
variation in timing of surgery in the longer interval group, from 61 to 474, adds to the body of previous
published evidence that there is a wide variation in the scheduling of surgery following preoperative treatment.
[1] This variation is in part attributable to patient choice and/or waiting list problems. However, the lack of
clarity regards the standard of care in timing of surgery following completion of preoperative
chemo/radiotherapy is once again highlighted.
Preoperative chemo/radiotherapy for rectal cancer is used to reduce tumor stage and size, thus facilitating
complete resection and reducing the incidence of local recurrence. Potentially, greater tumor downsizing may
allow greater rates of sphincter saving surgery and reduce the need for permanent stomas. In 1999,
Francois et al. randomized 201 patients to surgery at 2 or 6 weeks following completion of radiotherapy.
The longer interval group had better tumor response and pathological down-staging and higher sphincter
saving surgery rates.[2] Since the Lyon R90-01 trial, surgeons have operated at approximately 6-8 weeks
after the completion of preoperative therapy. More recent studies have observed ongoing down-staging and
better surgical outcomes with a delay of longer than 8 weeks.[3,4] Ideally, surgery should take place at the
time of maximal response to the radiotherapy, the effects of which are known to be time dependent.
In our own cancer networks published retrospective review of rectal cancers treated preoperatively over a
27-month period, 32 (34%) patients underwent surgery at 6-8 weeks, 45 (47%) at >8 weeks and 18 (19%)
at <6 weeks after radiotherapy.[1] Delay was attributed to scheduling in 87% of cases and comorbidities in
the remainder. Tumor downstaging occurred in 6 (33.3%) patients in <6 weeks group, 12 (37.5%) in 6-8
weeks group, and 28 (62.2%) for >8 weeks with no significant differences in perioperative morbidity. More
patients were staged ypT0-T2, 19/45 (42%) in the >8 weeks group versus other groups, 14/50 (28%, P <
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0.05). We therefore concluded that following chemo/radiotherapy, surgery frequently occurs >8 weeks and is
associated with increased downstaging, but that the consequences on survival and perioperative morbidity
warranted further investigation.
Post-NACTRT both circumferential resection margin and tumor stage have a direct correlation with the
likelihood of local recurrence.[5] With a number of studies demonstrating an ongoing response to
preoperative therapy beyond the 6-8 weeks window,[3,4] it seems logical that surgery prior to 8 weeks
maybe premature, in all but those who have progressive disease on interim scans. Those patients with a
complete pathological response following chemo/radiotherapy for rectal cancer have a significantly better long
term outcome.[5,6] The presented study was not powered to examine the relationship between pathological
complete remission (CR) (n = 22) and timing of surgery. However, more patients in the delayed group (>60
days) had a pathological CR (23% vs. 14%). Previous work has shown that a greater delayed to surgery
following completion of preoperative therapy is associated with an increased likelihood of achieving a
pathological CR.[6]
There is sufficient published evidence to suggest that there is ongoing local down-staging beyond 8 weeks in
many patients. However, while some centers have now moved to routinely operating with longer delays, there
is a concern that such delays cause deferral of systemic chemotherapy, and create the risk of inadvertent
progression of systemic disease. Hence, a number of key questions need to be addressed before any change
in the standard of care can occur. First, does a delay to surgery improve local recurrence rates? Is there an
increase in surgical complications, and if so does this result in a delay to adjuvant therapy? With a longer
interval, is there an increased risk of disease progression, either local or metastatic? As highlighted by this
study, only with a prospective randomized controlled multicenter study with strict adherence to the timing of
surgery can level I evidence be provided that can finally answer these questions and controversy removed
from an area of such clinical and academic importance.
With this in mind the Royal Marsden Hospital designed and launched the 6 versus 12 study
(http://www.clinicaltrials.gov/show/NCT01037049) and the French trial (Greccar 6) was designed,
randomizing between 7 and 11 weeks (http://www.clinicaltrials.gov/show/NCT01648894). These multicenter
prospective randomized controlled trials are powered with the primary aim of determining whether greater
rectal cancer down-staging and regression occurs with a greater delay to surgery after completion of
chemo/radiotherapy. The secondary aims include sphincter saving surgery rates, early surgical complications,
diversion stoma rates positron emission tomography-computed tomography and magnetic resonance imaging
monitoring and response, radiotherapy-related bowel toxicity and recurrence free survival.
The 6 versus 12 study and Greccar trials will be the first prospective randomized studies examining the
optimum time interval between completion of chemo/radiotherapy and surgery in the treatment of locally
advanced rectal cancer since the Lyon R90-01 trial in 1999. The potential impact of identifying the optimum
time to operate will be to the individual patient, the health care provider and future clinical trials. By identifying
the time of maximal response local recurrence and sphincter saving surgery rates and hence functional
outcome may be improved. This will add to the potentially reduced cost implications to healthcare providers
along with clarity for scheduling of surgery. The establishment of a “gold standard” in the timing of surgery
following NACTRT for locally advanced rectal cancer, will add the design of future trials by removing a
variable that currently exists.
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